DK104409C - Fremgangsmåde til fremstilling af quinazolonderivater eller syreadditionssalte deraf. - Google Patents

Fremgangsmåde til fremstilling af quinazolonderivater eller syreadditionssalte deraf.

Info

Publication number
DK104409C
DK104409C DK245564AA DK245564A DK104409C DK 104409 C DK104409 C DK 104409C DK 245564A A DK245564A A DK 245564AA DK 245564 A DK245564 A DK 245564A DK 104409 C DK104409 C DK 104409C
Authority
DK
Denmark
Prior art keywords
preparation
acid addition
addition salts
quinazolone derivatives
quinazolone
Prior art date
Application number
DK245564AA
Other languages
English (en)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK104409C publication Critical patent/DK104409C/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK245564AA 1963-05-18 1964-05-15 Fremgangsmåde til fremstilling af quinazolonderivater eller syreadditionssalte deraf. DK104409C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEF39784A DE1231705B (de) 1963-05-18 1963-05-18 Verfahren zur Herstellung von 2, 3-substituierten Chinazolon-(4)-derivaten
DEF0042147 1964-02-28

Publications (1)

Publication Number Publication Date
DK104409C true DK104409C (da) 1966-05-16

Family

ID=25975761

Family Applications (3)

Application Number Title Priority Date Filing Date
DK245564AA DK104409C (da) 1963-05-18 1964-05-15 Fremgangsmåde til fremstilling af quinazolonderivater eller syreadditionssalte deraf.
DK531064AA DK105765C (da) 1963-05-18 1964-05-15 Fremgangsmåde til fremstilling af quinazolon-derivater eller syreadditionssalte deraf.
DK531164AA DK106039C (da) 1963-05-18 1964-05-15 Fremgangsmåde til fremstilling af quinazolon-derivater eller syreadditionssalte deraf.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK531064AA DK105765C (da) 1963-05-18 1964-05-15 Fremgangsmåde til fremstilling af quinazolon-derivater eller syreadditionssalte deraf.
DK531164AA DK106039C (da) 1963-05-18 1964-05-15 Fremgangsmåde til fremstilling af quinazolon-derivater eller syreadditionssalte deraf.

Country Status (10)

Country Link
US (1) US3322756A (da)
AT (3) AT258918B (da)
BE (1) BE648093A (da)
CH (3) CH447181A (da)
DE (2) DE1231705B (da)
DK (3) DK104409C (da)
FR (1) FR3806M (da)
GB (1) GB1053063A (da)
NL (1) NL6405448A (da)
SE (3) SE314074B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1003802A (en) * 1963-06-04 1965-09-08 Searle & Co Pyrimidinone derivatives
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
DE2027645A1 (de) * 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US3900476A (en) * 1973-05-17 1975-08-19 Upjohn Co 2(2'-pyrimidylamino)quinazolines and their preparation
US3936453A (en) * 1974-01-28 1976-02-03 Sandoz, Inc. 1-Substituted-2-disubstituted aminoquin azolin-4(1h)-ones
US3959279A (en) * 1974-01-28 1976-05-25 Sandoz, Inc. 1-Substituted-2-imino-quinazolin-4(1H)ones
US4113637A (en) * 1974-09-10 1978-09-12 Institut Francais Du Petrole Alkyl-guanidino-heterocyclic compounds, their manufacture and use as additives for fuels and lubricants
GB8429739D0 (en) * 1984-11-24 1985-01-03 Fbc Ltd Fungicides
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
WO1997010221A1 (en) * 1995-09-15 1997-03-20 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries
US6258819B1 (en) * 1999-08-05 2001-07-10 Syntex (U.S.A.) Llc Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
PT1278748E (pt) 2000-04-25 2011-03-31 Icos Corp Inibidores de delta 3-cinase humana de fosfatidilinositol
US20040176361A1 (en) * 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESINS
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US7009049B2 (en) * 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
CA2485148A1 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003236527A1 (en) * 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
US7211580B2 (en) * 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AU2003277079A1 (en) * 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
BRPI0413452A (pt) 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2005030751A2 (en) * 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1682534A2 (en) * 2003-11-03 2006-07-26 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions, and methods
US20050148593A1 (en) * 2003-11-07 2005-07-07 Gustave Bergnes Compounds, compositions, and methods
WO2005061460A1 (en) * 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
GEP20094679B (en) * 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
JP2007537291A (ja) 2004-05-13 2007-12-20 イコス・コーポレイション ヒトホスファチジルイノシトール3−キナーゼデルタの阻害剤としてのキナゾリノン
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び/又は予防する方法
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
SI1942898T2 (sl) 2005-09-14 2014-08-29 Takeda Pharmaceutical Company Limited Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa
PE20070622A1 (es) * 2005-09-14 2007-08-22 Takeda Pharmaceutical Administracion de inhibidores de dipeptidil peptidasa
CA2622642C (en) * 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20100029941A1 (en) * 2006-03-28 2010-02-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
CA2914168C (en) 2006-03-28 2018-05-08 Atir Holding S.A. Pyrido[1,2-a]pyrimidin-4-one derivatives and their use in the treatment of sexual disorders
DK2073810T3 (da) * 2006-09-13 2011-10-31 Takeda Pharmaceutical Anvendelse af 2-6-(3-aminio-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-ylmethyl-4-fluor-benzonitril til behandling af diabetes, cancer, autoimmune sygdomme og HIV infektion
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20120002995A (ko) 2009-03-24 2012-01-09 길리아드 칼리스토가 엘엘씨 2―퓨리닐―3―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
PT2421536E (pt) * 2009-04-20 2015-10-20 Gilead Calistoga Llc Métodos de tratamento para tumores sólidos
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
NZ720867A (en) 2013-12-20 2018-01-26 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
CH447183A (de) 1967-11-30
NL6405448A (da) 1964-11-19
DK105765C (da) 1966-11-07
SE314074B (da) 1969-09-01
AT258917B (de) 1967-12-27
BE648093A (da) 1964-11-19
DE1249281B (da)
AT254193B (de) 1967-05-10
CH447181A (de) 1967-11-30
SE314076B (da) 1969-09-01
SE314075B (da) 1969-09-01
US3322756A (en) 1967-05-30
DE1231705B (de) 1967-01-05
GB1053063A (da)
FR3806M (fr) 1966-01-03
AT258918B (de) 1967-12-27
CH447182A (de) 1967-11-30
DK106039C (da) 1966-12-12

Similar Documents

Publication Publication Date Title
DK105765C (da) Fremgangsmåde til fremstilling af quinazolon-derivater eller syreadditionssalte deraf.
DK108972C (da) Fremgangsmåde til fremstilling af lipoylpyridoxamin eller syreadditionssalte deraf.
DK125421B (da) Analogifremgangsmåde til fremstilling af 5-substituerede-aza-dibenzo-cycloheptener eller syreadditionssalte deraf.
DK106733C (da) Fremgangsmåde til fremstilling af 3-hydroxy-5-aminomethyl-isoxazol eller syreadditionssalte deraf.
DK109897C (da) Fremgangsmåde til fremstilling af bis-alkanolaminderivater eller deres syreadditionssalte.
DK116362B (da) Fremgangsmåde til fremstilling af basisk substituerede benzothiazepinderivater eller syreadditionssalte deraf.
DK116000B (da) Fremgangsmåde til fremstilling af amino-halogen-benzylaminer eller syreadditionssalte heraf.
DK119059B (da) Fremgangsmåde til fremstilling af 2-nitro-imidazolderivater eller syreadditionssalte deraf.
DK129924B (da) Analogifremgangsmåde til fremstilling af aminoalkylaminobenzophenonderivater eller syreadditionssalte deraf.
DK117636B (da) Fremgangsmåde til fremstilling af diazocin- eller diazecinderivater eller syreadditionssalte deraf.
DK109142C (da) Fremgangsmåde til fremstilling af 4-aminoquinolinderivater eller syreadditionssalte deraf.
DK103831C (da) Fremgangsmåde til fremstilling af 4-azathioxanthenderivater eller syreadditionssalte deraf.
DK106335C (da) Fremgangsmåde til fremstilling af derivater af 16-hydroxymethylenyohimbanforbindelser eller syreadditionssalte deraf.
DK114485B (da) Fremgangsmåde fremstilling af imidazolderivater eller syreadditionssalte deraf.
DK112029B (da) Fremgangsmåde til fremstilling af basiske ethano-anthracenderivater eller syreadditionssalte deraf.
DK108394C (da) Fremgangsmåde til fremstilling af substituerede imidazo- eller pyrimido-quinazoliner eller syreadditionssalte deraf.
DK121604B (da) Fremgangsmåde til fremstilling af substituerede iminocycloheptatrienderivater eller syreadditionssalte heraf.
DK107098C (da) Fremgangsmåde til fremstilling af 5-hydrazino-pyrazol-derivater eller syreadditionssalte deraf.
DK105649C (da) Fremgangsmåde til fremstilling af 2-dimethylaminopyrazin eller syreadditionssalte deraf.
DK111893B (da) Fremgangsmåde til fremstilling af substituerede methylhydraziner eller syreadditionssalte deraf.
DK112171B (da) Fremgangsmåde til fremstilling af benzimidazoler eller syreadditionssalte deraf.
DK116211B (da) Fremgangsmåde til fremstilling af acridanderivater eller syreadditionssalte deraf.
DK122877B (da) Analogifremgangsmåde til fremstilling af fenylisopropylalkylaminderivater eller syreadditionssalte deraf.
DK107748C (da) Fremgangsmåde til fremstilling af 5-nitropyrrolderivater eller syreadditionssalte deraf.
DK105764C (da) Fremgangsmåde til fremstilling af 1-azathioxanthenderivater eller syreadditionssalte deraf.